NYSEHealth CareHealthcare PlansSnapshot 2026-07-31
Reading CVS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Revenue at least $405 billion in fiscal 2026: revenue guidance $400 billion vs target $405 billion.
View ThesisRevenue is growing steadily — about 8% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskCVS's growth depends on its ability to increase adjusted EPS guidance. The company recently raised its EPS guidance to $7.30 per share. It beat earnings expectations by 16% in the last quarter. CVS trades at 15× P/E, below the peer median of 22×. This suggests that the price reflects less growth than expected. A specific risk is the potential for a guidance cut, with a 10% miss probability. Peer multiples imply a price roughly in line with where it trades. Our read is provisional.
Trailing returns as of 2026-07-31. CVS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 28 analysts currently covering CVS (as of Jul 2026).
Based on 13 Wall Street analysts offering 12-month price targets for CVS in the last 4 months.
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Services — fair value, gap to price, and forward P/E.
340B pricing lawsuit could impact revenue and cash flow.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $104.43
The last 12 months of price, then the range of analyst 12-month targets from today’s $104.43.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Increase cash flow from operations
Capital investments support increased cash flow from operations.
Lawsuit could impact financial stability and operational cash flow.
Advances: Increase adjusted EPS guidance
Improved execution supports EPS growth outlook.
Settlement may reduce legal risks and improve operational focus.
Drug pricing changes could enhance competitive positioning.
Counting TrumpRx purchases could improve revenue stability.
Confirmed settlement supports CVS's drug pricing strategy.
